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 Implication for health policy/practice/research/medical education:
Readers of this manuscript will realize that Hepatitis C virus and Human Immunodeﬁciency virus co-infections have important 
impacts on the management of hepatitis B chronic patients. In addition this study will attract the attention of health policy-mak-
ers towards some routes of infection transfer like periodontal procedures, which generally are ignored, but need to be monitored 
more strictly. 
Copyright  c 2011 Kowsar M. P. Co. All rights reserved. 
Background: Co-infection with hepatitis C virus (HCV) and/or human immunodeﬁciency 
virus (HIV) in patients with chronic hepatitis B virus (HBV) infection can alter the course 
of the disease.
Objectives: In this study, we investigated the frequency of HIV and/or HCV co-infection in 
chronic HBV patients and related risk factors in acquiring the HCV and or HIV co-infec-
tionit.
Patients and Methods: We studied 264 chronic HBV patients who visited the Gastroin-
testinal and Liver Ward of the Taleghani Hospital, Tehran, Iran between 2006 and 2010. 
Demographic information and records of possible risky behavior were obtained. An-
tibodies against HBV, HCV, and HIV, levels of alanine transaminase (ALT) and aspartate 
transaminase (AST), and conversion from hepatitis B e antigen (HBeAg) to hepatitis B e 
antibody (HBeAb) were evaluated.
Results: Of 264 patients with chronic HBV in this study, 184 patients (70%) were men and 
78 patients (30%) were women. Only 1 patient (0.37%) was positive for anti-HIV antibody, 
whereas 12 patients (4.54%) were positive for anti-HCV antibody. None of the patients had 
co-infection with all 3 viruses (HBV, HIV, and HCV).
Conclusions: This study demonstrated that the prevalence of HCV is higher than that of 
HIV in chronic HBV patients. Since HCV or HIV co-infection aﬀects the therapeutic out-
come in chronic HBV patients, testing for HIV and HCV is recommended, especially for 
patients with a history of risky behavior.
Hepat Mon. 2011;11(12):993-996. DOI: 10.5812/kowsar.1735143X.740
1. Background
Human immunodeﬁciency virus (HIV), hepatitis C 
virus (HCV), and hepatitis B virus (HBV) are among the 
most important infectious agents in the world and are 
considered a noteworthy problem. These viruses have 
similar epidemiologic properties and transmission 
routes. About 2 billion people worldwide have been in-994
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fected with HBV and about 350 million are chronically 
infected (1). In 1979, the prevalence of HBV was 2.2–7% in 
the Iranian population (2), but according to recent re-
ports, the prevalence of HBV in Iran has decreased to less 
than 2% (3). HCV has infected 170 million people, approxi-
mately 3% of the world population (4). According to a re-
cent study, 0.093% of the Iranian blood donor population 
is infected with HCV (5). This infection progresses into 
chronic disease and eventually leads to cirrhosis and 
sometimes  hepatocellular  carcinoma.  HIV  is  the  caus-
ative agent of Acquired Immunodeficiency Syndrome 
AIDS and although there has been significant progress in 
diagnosis, pathogenesis, and treatment of this disease, 
a preventive vaccine or absolute cure for this disease 
remains out of sight. Just in 2007, 2 million people died 
because of AIDS; in the same year, 2.7 million people were 
infected by this virus (6). of the blood donor population 
in Iran, 0.003% are infected with this virus (5).
Almost  one  third  of  HIV-infected  patients  in  europe 
and America are co-infected with HCV, and 10% of HIV-
infected patients are co-infected with HBV (7). In a recent 
study performed in Iran, researchers found that the se-
roprevalence  in  the  general  population  was  0.56%  for 
HBV, 0.13% for HCV, and 0.004% for HIV (8). With regard to 
co-infections, most studies in Iran have been performed 
on inmates or hospitalized drug abusers. These studies 
showed that HBV-HCV co-infection is frequent, whereas 
triple co-infection was never observed (9-11). Co-infection 
of HBV with HCV or HIV could play a critical role in the 
course of the disease and efficacy efficiency of treatment 
(7). Therefore, evaluation of chronic HBV patients for co-
infection with HCV or HIV has great importance for phy-
sicians in choosing a treatment regimen and in consider-
ing disease progression.
2. Objectives
There is scarce information on the prevalence of co-in-
fection with HCV or HIV in Iranian chronic HBV patients. 
This study intended to evaluate the prevalence of co-
infection with HCV or HIV in chronic HBV patients who 
were referred to the Gastrointestinal and Liver Ward of 
the Taleghani Hospital, Tehran, Iran.
3. Patients and Methods
Two hundred and sixty four chronic hepatitis B patients 
who were patients in the Gastrointestinal and Liver Ward 
of the Taleghani Hospital between 2006 and 2010 were 
enrolled in this descriptive cross-sectional study. Written 
informed consent was obtained from all patients prior 
enrollment in this study. After obtaining each patient’s 
demographic information and records of any risky behav-
ior, including intravenous drug abuse, dangerous sexual 
contacts, cupping, hemodialysis, blood transfusion, tat-
tooing, needle stick injury, dentistry operations, and use 
of shared razors, blood specimens were collected from 
each  patient.  Serum  was  separated  from  whole  blood 
and tested for the level of liver enzymes, e.g., alanine 
transaminase (ALT) and aspartate transaminase (AST), by 
using an auto-analyzer (Liasys, Germany). The rest of the 
blood sample was stored at -70°C for further serologic 
tests.  For  confirmation  of  HBV  infection,  an  enzyme-
linked immunosorbent assay (eLISA) technique (Diapro, 
Italy) was used for detection of hepatitis B surface anti-
gen (HBsAg) and anti-hepatitis B core protein antibody 
(anti-HBcAb). To determine the status of conversion from 
hepatitis B e antigen (HBeAg) to hepatitis B e antibody 
(HBeAb) in patients, we used an eLISA technique (Diapro) 
designed for HBeAg and anti-HBeAb. In the next phase of 
this study, the infection of these patients with HIV and 
HCV was assessed using an eLISA technique (Diapro) for 
the presence of anti-HCV and anti-HIV 1 and 2 antibodies. 
Samples with a positive result were tested again for con-
firmation. Data were analyzed by using SpSS 19 statistical 
software (SpSS Inc, Chicago, Illinois, USA).
4. Results
A total of 264 patients were enrolled in this study, in-
cluding 184 men (70%) and 78 women (30%). The mean 
age of the patients was 41.58 ± 13.95 years (range: 11 to 77 
years). All enrolled patients had prior knowledge of their 
infection, but for confirmation of their infection status, 
we tested them again for HBsAg and HBcAb. With regard 
to their status conversion from HBeAg to HBeAb, 32 pa-
tients (12%) were positive for HBeAg and negative for anti-
HBeAb, 221 patients (84%) were anti-HBeAb-positive and 
HBV Alone HBV+HCV HIV Total
Gender
Male
Female
173
76
10
2
1
0
184
78
HBeAg,  no.a
P
n
32
219
0
12
0
1
32
232
HBeAb,  no.a
P
n
208
43
12
0
1
0
221
43
Table. Patient Demographic and Serologic Information
a Abbreviation: HBeAg, hepatitis B e antigen; HBeAb hepatitis B e antibody995
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HBeAg-negative, and 11 patients (4%) were negative for 
both markers (Table). HCV antibody was detected in 12 
patients. In these patients, history of drug abuse (38.5%) 
and high-risk sexual contacts (33%) were the most-cited 
risky behaviors, and blood transfusion (4.3%) and hemo-
dialysis (0%) were the least frequent high-risk behaviors. 
only  1  patient  was  HIV  antibody-positive.  This  patient 
was a 31-year-old man and an intravenous drug abuser. 
He also had a history of hemodialysis and periodontal 
procedures. He had no history of high-risk sexual con-
tacts, use of shared blade razors, cupping, and tattooing. 
Interestingly, in the group of patients who had only HBV 
infection, the most prevalent risk factor was periodontal 
operation (28.8%), whereas intravenous drug abuse was 
really low in this group (3%) compared to HCV-co-infect-
ed patients.
5. Discussion
The results of this study showed that in chronic HBV pa-
tients, the prevalence of HCV is higher in comparison to 
HIV. Studies on HBV with HCV and HIV co-infections are 
increasing and have attracted the attention of research-
ers all over the world. HBV and HCV are among the main 
causes of liver problems. In addition, faster disease pro-
gression and higher occurrence of liver problems such 
as cirrhosis and hepatocellular carcinoma have been 
shown in co-infected patients compared to patients with 
only chronic HBV infection (7, 12, 13). on other hand, the 
treatment regimen for patients with HCV co-infection in 
chronic HBV patients is different from that for patients 
with only HBV infection (9). In addition, clinical stud-
ies  have  shown  that  HIV  co-infection  in  chronic  HBV 
patients can alter the natural course of the disease and 
treatment choices (14-16). In the current study, a com-
parison  of  chronic  HBV  patients  without  co-infection 
and those with HCV co-infection showed that co-infect-
ed patients were more likely to be engaged in high-risk 
behaviors. Interestingly, while intravenous drug addic-
tion was the most prevalent risk factor in co-infected pa-
tients, we observed that co-infected patients mentioned 
a history of sharing razors more frequently than patients 
infected only with HBV. In addition, the majority of pa-
tients reported periodontal procedures as a part of their 
medical history, which points to the possibility of trans-
ferring the infection through this route. A study of age 
distribution showed that the majority of non-co-infected 
patients were between 30 and 40 years of age, while co-
infected patients were between 40 and 50 years of age. 
We could imply from this observation that the younger 
subjects,  with  higher  health  standards,  could  be  less 
prone to co-infection.
In other parts of the world, researchers found different 
rates of co-infection. In a study performed in Kenya on 
HIV seropositive patients, the investigator reported that 
23 patients (6%) had co-infection with HBV and HIV, 4 pa-
tients (1%) were co-infected with HCV and HIV, and 1 pa-
tient (0.25%) was infected with all 3 viruses (17). In a study 
performed in the emergency department of a local hos-
pital in Michigan, USA, investigators found that there was 
no co-infection and the prevalence of HBV, HCV, and HIV 
was 0.7%, 4%, and 0.8%, respectively (18). In a study of drug 
abusers in Georgia, researchers reported that the infec-
tion rate for HBV, HCV, and HIV was 55.2%, 68.8%, and 1.7%, 
respectively (19). In studies performed in Iran, research-
ers reached different rates of co-infection. In a study of 
hospitalized drug abusers in Kashan, Iran, Shariff and 
colleagues observed that 1% of inmates had a co-infection 
of HBV and HCV, but none of the inmates had triple co-
infection (10). Alavi and colleagues performed a study on 
co-infection of HBV and HCV with HIV in 104 HIV-positive 
drug  addicts  who  were  hospitalized  in  the  infectious 
ward of the Razi Hospital, Ahvaz, Iran, between 2001 and 
2003. They found that the prevalence of infection with 
HCV and HBV among these patients is very high (74.4% 
and 44.23%, respectively) (9). In 2004, Torabi studied 162 
hemophiliacs who lived in the eastern Azerbaijan prov-
ince, Iran, for infection with HIV, HCV, and HBV and their 
prevalence was 0.6%, 51%, and 1.18%, respectively (11). In 
light of the results reported in this study, we recommend 
that screening for HIV infection should be only executed 
for chronic HBV patients with a history of risky behavior, 
while screening for HCV co-infection should be manda-
tory for every chronic HBV patient.
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